SHARON, Pa., April 7 /PRNewswire-FirstCall/ -- Infectech, Inc., (Pink Sheets: IFEC), a Nanobiotechnology company engaged in the research, development and commercialization of technologies for the production of bacteria and disease testing kits, alternative sources of fuel, cancer therapy and remediation of toxic materials, announced today that the company has changed its name to NANOLOGIX, INC. The Company's name change was approved in a March 30 special meeting, during which a proposal to reverse split the company's common stock was turned down due to resistance from minority shareholders. The convergence of science, medicine and technology is on the cusp of yielding extraordinary breakthroughs. Today, patents that were once designed to identify bacteria have widespread applications across multiple markets. At the heart of this convergence is nature. All things begin and end with the building blocks of life. NanoLogix's portfolio of 31 patents have yielded a method vital to the development of nanotechnology products, a method for low cost hydrogen production, FDA registered products in the medical device industry, a genomic cancer therapy and methods for cleaning up toxic environments using bioremediation. According to Lux Research, sales of products that incorporate nanotechnology are expected to explode over the next five years, from $12.98 billion in 2004 to an estimated $507.74 billion in 2010. The following validates the value of NanoLogix's broad patent portfolio along with its current and future product lines. NanoLogix's patents have nanotechnology applications in hydrogen gas production, medical drugs/devices, bio-defense sensors and bioremediation. Nanotechnology applications include Biochips embedded in small transportable devices for rapid bacteria identification of disease causing pathogens, and Bio Micro Electro Mechanical Systems ("BioMEMS") for rapid environmental microbial monitoring with bio-defense implications. Its hydrogen bioreactor research is designed to assist in worldwide energy independence and reduce pollution using renewable, environmentally-friendly energy sources. NanoLogix's FDA registered diagnostic test kits are designed to be used for the rapid identification of infectious human diseases and identify 34 disease- producing bacteria, including Tuberculosis (TB), Mycobacterium avium- intracellulare (MAI), Pseudomonas, and Nocardia. These bacteria are cited as prominent causes of morbidity and mortality in patients with cancer, cystic fibrosis, and AIDS, as well as in patients undergoing surgery. Additionally, NanoLogix owns a patent for the nontoxic induction of apoptosis in cancer cells utilizing hydrophobic hydrocarbons. Apoptosis is a method for inducing a genetically based induction of "cell suicide" in cells. It therefore serves as the foundation for cancer therapy. NanoLogix's other patents include technology designed for use in the bioremediation of contaminated soil and water. For a detailed report on NanoLogix please visit: http://www.biotechstocksignals.com/ifec.pdf Investment Highlights: -- FDA Registration of Identikits. NanoLogix receives medical device exemption from FDA and can begin manufacturing and selling its biophasic system devices which detect Mycobacterium Tuberculosis (TB), Mycobacterium avium complex (MAC), Paratuberculosis, Pseudomonas, Nocardia and up to 34 different bacteria. -- The Indian Journal of Tuberculosis publishes Mahatma Gandhi Institute of medical Sciences research for isolation of Mycobacterium Avium Complex (MAC) using NanoLogix patented paraffin baiting technology. -- Ohio State University validates NanoLogix patented paraffin baiting technology. -- NanoLogix signs deal with Gannon University to build hydrogen bioreactor. -- NanoLogix in discussions with one of the largest juice company in U.S. to demonstrate feasibility of a pilot scale unit to convert millions of gallons of wastewater per year into hydrogen gas. -- The Royal Society of Chemistry publishes University of Cincinnati research for developing Biochips using NanoLogix patented paraffin baiting technology. -- National Science Foundation awards grant to University of Cincinnati for BioMEMS research using NanoLogix's patented paraffin baiting technology. -- NanoLogix granted patent for nontoxic genomics therapy for cancer. -- Journal of Laboratory Technology for Bioresearch (BioTechniques) publishes NanoLogix's research on cell death using hydrophobic hydrocarbons. About NanoLogix, Inc. NanoLogix, Inc., http://www.infectech.com , is a technology application innovator of biogas products and services designed to assist in worldwide energy independence and reduce pollution from renewable, environmentally- friendly energy sources. NanoLogix is also engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious human diseases. The Company's patents span the identification and antibiotic sensitivity testing of 34 disease-producing bacteria, including M. tuberculosis (TB), Mycobacterium avium-intracellulare (MAI), pseudomonas, and nocardia. These bacteria are cited as prominent causes of morbidity and mortality in patients with cancer, cystic fibrosis, and AIDS. Additionally, NanoLogix owns a patent for the nontoxic induction of apoptosis in cancer cells utilizing hydrophobic hydrocarbons. Apoptosis is a method for inducing a genetically based induction of "cell suicide" in cells. The Company's 31 patents can be viewed by visiting http://www.infectech.com/intellectual_property.php . This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward- statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
SOURCE Infectech, Inc.